Ardelyx (ARDX) Aktienübersicht
Ardelyx, Inc. erforscht, entwickelt und vermarktet Medikamente zur Behandlung ungedeckter medizinischer Bedürfnisse in den Vereinigten Staaten und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 6/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
ARDX Community Fair Values
Create NarrativeSee what 134 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ardelyx, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$3.92 |
| 52-Wochen-Hoch | US$8.40 |
| 52-Wochen-Tief | US$3.86 |
| Beta | 0.73 |
| 1 Monat Veränderung | -24.62% |
| 3 Monate Veränderung | -37.48% |
| 1 Jahr Veränderung | -33.11% |
| 3 Jahre Veränderung | 11.68% |
| 5 Jahre Veränderung | 166.67% |
| Veränderung seit IPO | -72.22% |
Aktuelle Nachrichten und Updates
Recent updates
Narrative-Update • Aug 08
ARDX: Gastrointestinal Franchise Execution Will Drive Multiyear Earnings Turnaround Potential
Analysts have reduced their fair value estimate for Ardelyx to $8.00 from $13.00 as they factor in a slightly higher discount rate, more conservative revenue growth and profit margin assumptions, and a lower future P/E multiple following recent commentary on the CMS appeal outcome and near term Ibsrela sales expectations. Analyst Commentary Recent Street commentary on Ardelyx centers on how the CMS appeal outcome and near term Ibsrela sales expectations feed into valuation and execution risk.Narrative-Update • Jun 25
ARDX: Expanding Gastrointestinal Franchise And Pipeline Will Support Multiyear Revenue Roadmap
Ardelyx’s analyst price target has shifted to $16. Analysts point to the focus on growing Ibsrela demand, sustaining Xphozah sales momentum, expanding the pipeline and meeting financial guidance as key drivers of their updated view.Analyseartikel • Jun 17
Ardelyx (ARDX) Stock Could Be 65% Undervalued As Growth Hopes Face Reassessment
Ardelyx (ARDX) is back in focus after recent trading, with the stock closing at $5.67 and showing mixed short term performance, including a decline over the past month and a gain over the past 3 months. See our latest analysis for Ardelyx. Looking beyond the latest move, Ardelyx’s share price return is down over the past month but slightly up over the past quarter, while its 1 year total shareholder return is strongly positive. This suggests earlier optimism is being reassessed rather than...
Narrative-Update • Jun 11
ARDX: Kidney And IBS Data Will Support Future Profitability Upside Potential
Analysts have kept Ardelyx's fair value estimate steady at about $16.33 per share, making only very small tweaks to inputs such as the discount rate, revenue growth, profit margin, and future P/E. This reflects largely unchanged expectations for the stock's longer term potential.Narrative-Update • May 28
ARDX: Kidney And IBS Data Will Support Longer-Term Upside Potential
Analysts have maintained Ardelyx's fair value estimate at $16.33 while modestly trimming the future P/E assumption. This reflects updated views on discount rate, revenue growth and profit margin inputs rather than a shift in the overall price target framework.Seeking Alpha • May 08
Ardelyx: Low Price, But High Implied Valuation
Summary Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optionality, potentially tripling IBSRELA's addressable market if successful. DCF analysis yields a base-case share price of $24.27, well above current levels, even excluding ACCEL trial upside. Options market sentiment is strongly bullish (P/C ratio 0.07), reflecting investor confidence in near-term upside following solid earnings momentum. Read the full article on Seeking AlphaNarrative-Update • May 05
ARDX: Extended 2042 Patent Protection Will Support Longer-Term Upside Potential
Analysts have nudged their average price target for Ardelyx higher to about $16.33 from $16.10, citing recent patent news that extends protection to November 2042 as a key support for this updated view. Analyst Commentary Bullish Takeaways Bullish analysts highlight the new patent protection to November 2042 as a key support for their higher valuation ranges, arguing that a longer exclusivity window can support the commercial life of Ardelyx's products.Analyseartikel • May 04
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
It's been a pretty great week for Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders, with its shares surging 15% to US$6.88 in...Narrative-Update • Apr 21
ARDX: Extended 2042 Patent Horizon Will Support Multiyear Revenue Roadmap
The analyst fair value estimate for Ardelyx has increased from $10.00 to $13.00, supported by recent price target revisions and analyst views that the new patent extending to November 2042 strengthens the company’s long-term profile. Analyst Commentary Recent research commentary around Ardelyx centers on the updated patent timeline to November 2042 and how that may influence valuation assumptions.
Narrative-Update • Apr 06
ARDX: Extended Patent Runway And 2029 Revenue Guidance Will Support Repricing
Ardelyx's consensus analyst price target has moved higher toward $19, with the shift largely tied to stronger Ibsrela revenue guidance, extended patent protection into the 2040s, and analyst expectations reflected in updated P/E, growth, and margin assumptions. Analyst Commentary Bullish analysts have been revising their views higher, with a series of price target increases and rating upgrades clustering around Ardelyx's updated Ibsrela guidance and extended patent protection.Narrative-Update • Mar 23
ARDX: Extended Patent Life And IBS Guidance Are Expected To Unlock Upside
The analyst fair value estimate for Ardelyx has been raised from $13.50 to $16.10. Analysts point to higher Ibsrela revenue guidance, extended intellectual property protection into the 2040s, and a series of upward revisions to Street price targets as key drivers of the change.Narrative-Update • Mar 09
ARDX: Extended Patent Runway And 2029 Revenue Outlook Will Drive Bullish Repricing
Ardelyx's analyst price target has moved higher, with several firms lifting their views into a $14 to $19 range. Analysts highlight extended patent protection on key assets, updated Ibsrela revenue guidance that includes targets of $410m to $430m in FY26 and $1b by 2029, and a stronger outlook for the broader product portfolio and cash position.Narrative-Update • Feb 22
ARDX: Extended Patent Runway And 2029 Revenue Path Will Support Bullish Outlook
The analyst fair value estimate for Ardelyx has shifted from $16.00 to $19.00, as analysts factor in higher projected revenue, updated profitability assumptions, and extended intellectual property protection highlighted in recent research notes. Analyst Commentary Recent Street research on Ardelyx has leaned firmly positive, with several bullish analysts lifting price targets and, in some cases, upgrading their ratings after management updates and new patent developments.Narrative-Update • Feb 08
ARDX: Multiyear Revenue Roadmap And CIC Expansion Will Drive Upside
Analysts lifted their fair value estimate for Ardelyx to $10.00 from $8.00, citing updated Street research that highlights stronger Ibsrela revenue guidance toward $410m to $430m by FY26 and a US$1b annual revenue outlook by 2029, along with pipeline progress and a solid cash position. Analyst Commentary Recent Street research has centered on Ibsrela guidance of US$410m to US$430m in FY26 and the long term US$1b annual revenue outlook for 2029, with several firms adjusting price targets and ratings to reflect those inputs, as well as updates on Xphozah, the broader pipeline, and the cash position.Narrative-Update • Jan 24
ARDX: Faster Path To 1b Revenue Is Expected To Unlock Upside
We are raising our Ardelyx fair value estimate from $12.30 to $13.50 as analysts point to higher Ibsrela revenue expectations, a faster ramp to the company’s $1b annual revenue goal, and updated guidance that supports stronger margins and a lower forward P/E multiple. Analyst Commentary Recent Street research is broadly constructive on Ardelyx, with multiple firms lifting price targets after the latest Ibsrela revenue outlook and guidance update.Analyseartikel • Jan 21
Ardelyx, Inc. (NASDAQ:ARDX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Ardelyx, Inc. ( NASDAQ:ARDX ) shares have continued their recent momentum with a 37% gain in the last month alone. The...Narrative-Update • Jan 09
ARDX: Higher Revenue Guidance Is Expected To Support Long Term Upside
Narrative Update on Ardelyx The analyst price target for Ardelyx has shifted higher, with our fair value estimate moving from US$11.60 to US$12.30 as analysts factor in stronger Ibsrela revenue guidance and updated Street targets of up to US$19. Analyst Commentary Recent Street research on Ardelyx has focused heavily on updated Ibsrela revenue guidance and how that might influence the company’s valuation and execution priorities over the next several years.Narrative-Update • Dec 25
ARDX: Long-Term Profitability Improvements Will Drive Stronger Bullish Outlook
Analysts have raised their price target on Ardelyx from 15 dollars to 16 dollars. This reflects slightly stronger expectations for long term revenue growth, improved profitability, and a modestly lower future earnings multiple despite a higher discount rate.Narrative-Update • Dec 11
ARDX: Upcoming Leadership Transition Will Support Long Term Earnings Upside
Analysts have modestly reiterated their confidence in Ardelyx, keeping the price target essentially unchanged at approximately 11.60 dollars per share. Minor adjustments to the discount rate and valuation inputs did not materially alter their long term earnings and growth outlook for the company.Narrative-Update • Nov 26
ARDX: Commercial Execution Will Drive Shares Higher Under New Leadership
Ardelyx’s analyst price target has been raised from $12 to $14, a $2 increase. Analysts cite stronger commercial execution and discounted valuation under new management as key drivers for the higher outlook.Narrative-Update • Nov 07
ARDX: Ongoing Commercial Execution Will Unlock Upside From Discounted Levels
Analysts have raised Ardelyx’s fair value estimate from $11.36 to $11.73, citing stronger commercial execution, increased revenue growth potential, and a more favorable profit margin outlook. Analyst Commentary Recent coverage initiations have highlighted key perspectives among market observers evaluating Ardelyx’s trajectory and valuation.Analyseartikel • Nov 02
Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its Third-Quarter Report
The investors in Ardelyx, Inc. 's ( NASDAQ:ARDX ) will be rubbing their hands together with glee today, after the share...Analyseartikel • Oct 11
Ardelyx, Inc. (NASDAQ:ARDX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
The Ardelyx, Inc. ( NASDAQ:ARDX ) share price has softened a substantial 26% over the previous 30 days, handing back...Analyseartikel • Jul 11
There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues Despite A 26% Share Price Rise
Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders would be excited to see that the share price has had a great month, posting...Analyseartikel • May 15
Benign Growth For Ardelyx, Inc. (NASDAQ:ARDX) Underpins Stock's 28% Plummet
To the annoyance of some shareholders, Ardelyx, Inc. ( NASDAQ:ARDX ) shares are down a considerable 28% in the last...
Neues Narrative • Apr 27
Omnichannel Investments And Sales Teams Will Create Future IBSRELA Demand
Strategic investments and an expanded sales team are expected to drive demand for IBSRELA, boosting revenue and market share.Seeking Alpha • Feb 24
Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)
Summary Ardelyx, Inc. faces significant challenges in 2025 due to Xphozah's reimbursement issues and modest growth from Ibsrela, prompting a downgrade to "sell" and "market underperform." Xphozah's inclusion in a bundled system and loss of Medicare Part D coverage limits revenue potential, despite the company's $750 million annual sales guidance. Increased SG&A expenses and looming debt obligations raise concerns about Ardelyx's ability to achieve consistent profitability and fund necessary R&D investments. ARDX has strong liquidity with a current ratio over 2, but cash-generating capability and limited pipeline cast doubt on sustaining a $1 billion-plus market valuation. Read the full article on Seeking AlphaAnalyseartikel • Feb 17
There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues
Ardelyx, Inc.'s ( NASDAQ:ARDX ) price-to-sales (or "P/S") ratio of 5.4x might make it look like a strong buy right now...Seeking Alpha • Dec 20
Ardelyx: A Small Bet Its Latest Setback Will Be Temporary
Summary Ardelyx's stock has fallen substantially after a court dismissed its lawsuit against the CMS, impacting Xphozah's profitability due to Medicare bundling changes starting January 2025. Ardelyx's tenapanor franchise, including Ibsrela and Xphozah, shows strong sales growth, but Xphozah's future is uncertain without Medicare Part D coverage. Management's gamble to avoid TDAPA and provide Xphozah for free to Medicare patients impacts profitability, but analysts remain optimistic with numerous Buy ratings. The stock now is trading at just over three times FY24 sales net of cash, presenting a 'speculative buy' opportunity. Read the full article on Seeking AlphaSeeking Alpha • Nov 24
Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It
Summary Ardelyx lost a lawsuit against Medicare, impacting XPHOZAH's revenue potential, with no other major prospects in its pipeline. CMS's decision to move XPHOZAH to the bundled payment system significantly reduces its revenue, forcing Ardelyx to negotiate complex reimbursements. The Kidney PATIENT Act, if passed, will delay the inclusion of oral-only ESRD drugs in the bundled payment system, benefiting Ardelyx until 2027. Despite the lawsuit loss, bipartisan support for the Kidney PATIENT Act offers hope for Ardelyx's financial stability and tenapanor's coverage. Read the full article on Seeking AlphaSeeking Alpha • Nov 14
Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability
Summary Ardelyx’s Q3 revenue grew to $98 million, with strong Xphozah sales despite CMS’s recent bundling ruling impacting future reimbursement. The CMS lawsuit dismissal affected Xphozah’s reimbursement prospects, creating significant regulatory uncertainty and limiting Ardelyx’s revenue control. Ibsrela faces substantial competition in the IBS-C market, with lofty revenue projections likely overstating its realistic market share. Ardelyx’s cash runway is around three years, bolstered by a $49.7 million loan, but rising SG&A expenses pose a long-term risk. I recommend a cautious hold for Ardelyx due to regulatory headwinds, competitive pressures, and uncertain long-term growth beyond tenapanor. Read the full article on Seeking AlphaAnalyseartikel • Nov 03
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Investors in Ardelyx, Inc. ( NASDAQ:ARDX ) had a good week, as its shares rose 5.5% to close at US$6.09 following the...Analyseartikel • Oct 24
Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business
With a price-to-sales (or "P/S") ratio of 6.3x Ardelyx, Inc. ( NASDAQ:ARDX ) may be sending very bullish signals at the...Analyseartikel • Aug 25
Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Aug 07
Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders will have a reason to smile today, with the analysts making substantial...Seeking Alpha • Aug 05
Ardelyx Faces Rising Challenges Despite Revenue Growth
Summary Ardelyx's Q2 2024 revenues increased significantly to $73.2 million from $22.3 million in Q2 2023. SG&A expenses rose to $64.7 million in Q2 2024 due to commercialization efforts for Ibsrela and Xphozah. Despite revenue growth, Ardelyx reported a net loss of $16.5 million in Q2 2024, similar to Q2 2023. Xphozah revenue growth is impressive, but challenges with reimbursement may impact future revenues. ARDX remains a "hold" with increased caution due to reimbursement challenges, ongoing operating losses, and competitive pressures. Read the full article on Seeking AlphaAnalyseartikel • Aug 04
Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Ardelyx, Inc. ( NASDAQ:ARDX ) just released its latest second-quarter results and things are looking bullish. The...Seeking Alpha • Jul 13
Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook
Summary Ardelyx declined last week after the company said it will not apply for TDAPA with the CMS for Xphozah to be included in the bundle in 2025. Legislative efforts may provide temporary relief for Xphozah, but its long-term future remains uncertain. The uncertainty around Xphozah put more pressure on Ibsrela to perform in the IBS-C market. Ardelyx can deliver long-term shareholder value based on Ibsrela alone and Xphozah offers significant upside optionality. Read the full article on Seeking AlphaAnalyseartikel • Jul 05
Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge
The Ardelyx, Inc. ( NASDAQ:ARDX ) share price has fared very poorly over the last month, falling by a substantial 25...Seeking Alpha • May 10
Ardelyx: Strong Execution, Fairly Valued
Summary Ardelyx has seen a substantial increase in its stock price since late 2022, when we last profiled the company, and Ardelyx recently posted better-than-expected quarterly results. The company has done a good job managing the launch of its flagship drug tenapanor, which is now approved for two indications. Ardelyx is posting impressive sales growth and is projected to be profitable in FY2025. An updated analysis around Ardelyx follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • May 04
Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Ardelyx, Inc. ( NASDAQ:ARDX ) defied analyst predictions to release its first-quarter results, which were ahead of...Aktionärsrenditen
| ARDX | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -0.5% | 1.8% | -0.3% |
| 1Y | -33.1% | 40.4% | 19.9% |
Rendite im Vergleich zur Industrie: ARDX unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 40.4% erzielte.
Rendite vs. Markt: ARDX hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 19.9 erzielte.
Preisvolatilität
| ARDX volatility | |
|---|---|
| ARDX Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: ARDX hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: ARDXDie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2007 | 489 | Mike Raab | www.ardelyx.com |
Ardelyx, Inc. erforscht, entwickelt und vermarktet Medikamente zur Behandlung ungedeckter medizinischer Bedürfnisse in den Vereinigten Staaten und international. Das Unternehmen bietet IBSRELA, eine minimal absorbierte niedermolekulare Therapie zur Behandlung von Patienten mit Reizdarmsyndrom mit Verstopfung, und XPHOZAH, einen Phosphatabsorptionshemmer zur Senkung des Serumphosphors bei Erwachsenen mit chronischer Nierenerkrankung unter Dialyse an. Ardelyx, Inc. war früher als Nteryx, Inc. bekannt und änderte im Juni 2008 seinen Namen in Ardelyx, Inc. um.
Ardelyx, Inc.'s Grundlagenzusammenfassung
| ARDX grundlegende Statistiken | |
|---|---|
| Marktanteil | US$1.01b |
| Gewinn(TTM) | -US$55.70m |
| Umsatz(TTM) | US$450.89m |
2.2x
Kurs-Umsatz-Verhältnis-17.5x
Kurs-Gewinn-Verhältnis Ist ARDX zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ARDX Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$450.89m |
| Kosten der Einnahmen | US$112.62m |
| Bruttogewinn | US$338.28m |
| Sonstige Ausgaben | US$393.98m |
| Gewinn | -US$55.70m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.22 |
| Bruttomarge | 75.02% |
| Nettogewinnspanne | -12.35% |
| Schulden/Eigenkapital-Verhältnis | 186.7% |
Wie hat sich ARDX auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/18 05:55 |
| Aktienkurs zum Tagesende | 2026/08/18 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Ardelyx, Inc. wird von 19 Analysten beobachtet. 11 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Julian Harrison | BTIG |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Yigal Nochomovitz | Citigroup Inc |